Transo-Pharm Expands Portfolio - Welcome on board, Norepinephrine Bitartrate

Epinephrine Base and Epinephrine Bitartrate have been in our portfolio even before we acquired the IP from the originator Boehringer Ingelheim. Over the last couple of years our customers have expressed their need for Norepinephrine Bitartrate and we listened.
 
We have proudly partnered up with hameln rds s.r.o. a Slovakian based API producer who has developed a robust Norepinephrine production process. The CEP has been issued by EDQM July 26, 2024. In this partnership, Transo-Pharm will focus on all commercial aspects and hameln rds will concentrate on production and quality.

Read More